← Leaderboards
Kyle Schachtschneider
University Of Illinois At Chicago
$1,191,072
Attributed
$2,382,143
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,382,143 · 2
By mechanism
R44$2,000,000 · 1
R21$382,143 · 1
Top collaborators
- Ron C Gaba2 shared
- Lawrence B Schook2 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Nissim Hay$25,480,567
- Tanvi Bhatt$8,410,612
- Ron C Gaba$1,001,057
- Alexander Richard Terry$240,850
- Sangeetha Madhavan$4,981,594
Others in their field
Other Emerging Leaders on “Treatment Response”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Prasant Mohapatra · University Of California At Davis$52,567,812
- Susan M Landau · University Of California Berkeley$47,252,026
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
Treatment ResponseTargeted TreatmentIn VivoIn Complete RemissionMutationResponseFamily SuidaeDrug MetabolismGeneticHepatocellular Carcinoma Cell LineMalignant Neoplasm Of LiverMalignant NeoplasmsPrimary Carcinoma Of The Liver CellsPrimary Malignant Neoplasm Of LiverCessation Of LifeClinically RelevantCancer EtiologyCancer ModelFutureCancer TypeGenotypeGrowthLiverTumor
Grant awards (4)
Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development$1,035,724
R44 · FY2024 · CA · contact PI
Validation of the Genetically Malleable Oncopig Hepatocellular carcinoma (HCC) Model for Targeted Therapeutic Development$964,276
R44 · FY2023 · CA · contact PI
Implications of Driver Mutations for Progression of Hepatocellular Carcinoma$243,090
R21 · FY2020 · CA
Implications of Driver Mutations for Progression of Hepatocellular Carcinoma$139,053
R21 · FY2019 · CA